CAMBRIDGE -
This award will support the Company's upcoming Phase 2 trial of IW-6463 in Alzheimer's Disease with vascular pathology (ADv). The award provides Cyclerion with
'We are very pleased to have won this highly competitive award from the Alzheimer's Association Part the Cloud-Gates Partnership Grant Program. Human genetic evidence and preclinical data suggest that stimulation of soluble guanylate cyclase (sGC) with IW-6463 can alleviate neurodegenerative pathology at the cellular level and thereby restore neuronal health and function. The clinical work supported by this grant will further our understanding of treatment potential of our approach and inform our efforts to find meaningful new treatments for dementias,' said
'As a practicing neurologist I have seen first-hand the devastating impact that dementias have on patients and their families. Patients and physicians are eager for better therapies and we need to explore new mechanistic approaches. We believe that IW-6463 has the potential to improve cognitive symptoms of dementia and may also be disease modifying - changing the course of many neurodegenerative diseases via potential neurovascular, neuroprotective, cellular bioenergetic, and neurophysiological benefits,' said
IW-6463 has successfully completed a Phase 1 study and is now being studied in a translational pharmacology study in elderly participants. Top line data from this study are expected in
About
About
As the world's largest nonprofit funder of Alzheimer's research, the
About IW-6463
IW-6463, a CNS-penetrant sGC stimulator, is being developed as a symptomatic and potentially disease modifying therapy for neurodegenerative diseases. In preclinical studies, IW-6463 has been associated with increased cerebral blood flow, reduced markers of neuroinflammation, enhanced cognition, neuroprotection and enhanced cellular bioenergetics. Nitric oxide is one of several fundamental neurotransmitters, but it has yet to be leveraged for its full CNS therapeutic potential. sGC stimulators work synergistically with the nitric oxide naturally produced in the body to boost the positive effects of nitric oxide, even when the body is not producing enough. Extensive human genetic and preclinical data implicate nitric oxide signaling defects in neurodegenerative diseases. Evidence indicates that nitric oxide dysregulation leads to vascular contributions to neurodegenerative disease (e.g. endothelial cell damage, decreased blood flow and impaired vascular reactivity) and may also directly increase inflammation, neuronal dysfunction/loss and cognitive impairment. sGC is expressed widely throughout the CNS and CNS vasculature. IW-6463 has successfully completed a Phase 1 study and is now being studied in a translational pharmacology study in elderly participants.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements about the anticipated timing of release of topline results of our clinical trials; the progression of our discovery programs into clinical development and the business and operations of Cyclerion. We may, in some cases use terms such as 'predicts,' 'believes,' 'potential,' 'continue,' 'anticipates,' 'estimates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'likely,' 'will,' 'should' or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Investors are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and Cyclerion undertakes no obligation to update these forward-looking statements, except as required by law. Applicable risks and uncertainties include the risks listed under the heading 'Risk Factors' and elsewhere in our 2019 Form 10-K filed on
Contact:
Email: ctanzi@kendallir.com
(C) 2020 Electronic News Publishing, source